Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07531498 · ClinicalTrials.gov registry record
Muscle Aging Phenotypes in Childhood Cancer Survivors
A clinical trial, sponsored by St. Jude Children's Research Hospital.
- Not yet
- Registry status
- 533
- Enrollment target
NCT07531498: Clinical Trial study, sponsored by St. Jude Children's Research Hospital.
NCT07531498 is a clinical trial that has not yet begun recruiting, run by St. Jude Children's Research Hospital. The registered enrollment target is 533 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07531498 has not yet begun recruiting, sponsored by St. Jude Children's Research Hospital.
- NOT YET RECRUITING
- Registry status
- 533 participants
- Enrollment target
Study Summary
Childhood cancer survivors experience premature declines in muscle mass, strength, and physical function that contribute to morbidity and early mortality. The biological mechanisms driving these impairments are heterogeneous and poorly understood. This observational study aims to characterize distinct muscle health endotypes in adult survivors of childhood cancer using advanced imaging, neuromuscular testing, and functional assessment. Survivors with reduced muscle health and community controls will undergo multimodal magnetic resonance imaging and spectroscopy, nerve conduction studies, surface electromyography, body composition assessment, and physical performance testing during a single study visit integrated into an ongoing cohort evaluation. Identifying mechanistic endotypes of impaired muscle health will support development of targeted interventions to preserve function and improve long-term outcomes in childhood cancer survivors. Primary Objective: \- Characterize reduced muscle health endotypes in childhood cancer survivors. Secondary Objective: \- Identify specific treatment and lifestyle related risk factors for each reduced muscle health endotype. Exploratory Objective: \- Host germline genetics will be associated with specific muscle endotypes.
Primary Outcome
Nerve conduction velocity (NCV) of sural sensory and tibial motor nerves will be performed using electromyography with standard landmarks for electrode placement. Compound Muscle Action Potential (CMAP) and Sensory Nerve Action Potential (SNAP) amplitudes are measured from negative to positive peak, and velocities calculated based on onset latency. NCV testing at rest and EMG during submaximal and maximal force generation will allow us to characterize the impact of the peripheral nervous system
Interventions
- OTHER Multimodal Muscle Imaging and Functional Assessment
- OTHER Multimodal Muscle Imaging and Neuromuscular Assessment
- OTHER Comprehensive Muscle Phenotyping
- OTHER Integrated Neuromuscular and Imaging Evaluation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 533 participants |
| Start Date | 2026-10-01 |
| Est. Completion | 2031-05 |
What is known before NCT07531498 opens enrollment
NCT07531498 is an observational study that tracks outcomes without assigning an intervention. The registered 533 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 4 interventions - of which Multimodal Muscle Imaging and Functional Assessment is the first listed.
NCT07531498 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07531498 about?
NCT07531498 is a clinical study titled "Muscle Aging Phenotypes in Childhood Cancer Survivors". Childhood cancer survivors experience premature declines in muscle mass, strength, and physical function that contribute to morbidity and early mortality. The biological mechanisms driving these impairments are heterogeneous and poorly understood. This observational study aims to characterize distin...
What is the current status of trial NCT07531498?
This trial is currently not yet recruiting. The enrollment target is 533 participants. The study started on 2026-10-01. Estimated completion is 2031-05.
What interventions are being tested in trial NCT07531498?
The interventions under investigation include: Multimodal Muscle Imaging and Functional Assessment (OTHER), Multimodal Muscle Imaging and Neuromuscular Assessment (OTHER), Comprehensive Muscle Phenotyping (OTHER), Integrated Neuromuscular and Imaging Evaluation (OTHER).
Who is sponsoring clinical trial NCT07531498?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04910685 · 534 participants · Phase 2
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
- NCT06128551 · 534 participants · Phase 1
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NCT05793151 · 532 participants · NA
Multi-Site Trial of Navigation vs Treatment as Usual to Improve Initiation of Timely Adjuvant Therapy
- NCT06378866 · 532 participants · Phase 2
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI